2 Holzman Street
Science Park PO Box 4081
Rehovot 7670402
Israel
972 8 940 6472
https://www.kamada.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 378
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Amir London | Chief Executive Officer | 611k | N/D | 1969 |
Mr. Chaime Orlev | Chief Financial Officer | 387k | N/D | 1970 |
Mr. Eran Nir | Chief Operating Officer | 332k | N/D | 1973 |
Mr. Jon R. Knight | Vice President of US Commercial Operations | 307k | N/D | 1966 |
Mr. Boris Gorelik | Vice President of Business Development & Strategic Programs | 410k | N/D | 1981 |
Mr. David Tsur | Co-Founder & Independent Deputy Chairman of the Board | 252k | N/D | 1950 |
Mr. Nir Livneh B.A., L.L.B. | VP, General Counsel & Corporate Secretary | N/D | N/D | 1980 |
Ms. Hanni Neheman | Vice President of Marketing & Sales | N/D | N/D | 1970 |
Ms. Liron Reshef | Vice President of Human Resources | N/D | N/D | 1972 |
Ms. Shavit Beladev | Vice President of Kamada Plasma | N/D | N/D | N/D |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
La calificación ISS Governance QuickScore de Kamada Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.